Coagulation monitoring during extracorporeal membrane oxygenation: The role of thrombelastography

A. H. Stammers, Lynne D Willett, L. Fristoe, J. Merrill, T. Stover, A. Hunt, J. Morrow, J. Newberry

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Patients undergoing extracorporeal membrane oxygenation (ECMO) are at an increased risk for developing coagulopathies due to the adverse effects of extracorporeal circulation on the hemostatic mechanism. Methods of determining causative factors of bleeding diathesis are often inconsistent and non-specific. ECMO patients require aggressive transfusion therapy with autogenic blood products to stabilize and maintain hemostasis. The present study evaluated the coagulation status of newborn patients undergoing ECMO therapy, using a viscoelastic monitor (Thrombelastograph -TEG) that measures functional aspects of clot development and stabilization. Seventeen neonatal patients undergoing ECMO for severe respiratory dysfunction were entered into this study. Serial blood samples were obtained and routine coagulation assessment including fibrinogen concentration, platelet count and ionized calcium was performed. In addition, fibrin (ogen) degradation products (FDP), d-Dimers, antithrombin III and plasma free hemoglobin were measured. Transfusion indicators were established and total transfusion requirements recorded. TEG profiles were determined with the use of heparinase, an enzyme that degrades heparin but has little effect on other coagulation factors. The most commonly encountered complication was hemorrhaging which was diagnosed by laboratory and clinical assessment in 11 of 17 patients. Transfusion requirements (measured in ml/kg/ECMO hour) were the following: packed red blood cells -1.34±0.5; platelets -0.71±0.57; fresh frozen plasma - 0.09±0.12; cryoprecipitate 0.05±0.05. Thrombelastograph profiles reflected hemostatic conditions that ranged from severe coagulopathies (DIC) to hypercoagulability. Interpretation of TEG profiles indentified hemostatic abnormalities in 57 of 101 profiles (46.5%), with the most common etiology related to platelet dysfunction. In the non-hemorrhagic group the TEG profiles were normal in 30 of 41 (73.2%) instances, while the hemorrhagic group had 24 of 60 (40%) profiles in the normal range (p<.001). d-Dimers and FDP were elevated in all patients during ECMO despite maintenance of activated clotting times greater than 180 seconds. During ECMO coagulation assessment with the TEG provides useful information for the rapid diagnosis of hemorrhagic conditions, which may help guide transfusion therapy.

Original languageEnglish (US)
Pages (from-to)137-145
Number of pages9
JournalJournal of Extra-Corporeal Technology
Volume27
Issue number3
StatePublished - Jan 1 1995

Fingerprint

Thrombelastography
Extracorporeal Membrane Oxygenation
Hemostatics
Blood Platelets
Heparin Lyase
Fibrin Fibrinogen Degradation Products
Dacarbazine
Blood Coagulation Factors
Thrombophilia
Extracorporeal Circulation
Antithrombin III
Disease Susceptibility
Hemostasis
Platelet Count
Fibrinogen
Heparin
Reference Values
Hemoglobins
Therapeutics
Erythrocytes

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Health Professions (miscellaneous)
  • Cardiology and Cardiovascular Medicine

Cite this

Stammers, A. H., Willett, L. D., Fristoe, L., Merrill, J., Stover, T., Hunt, A., ... Newberry, J. (1995). Coagulation monitoring during extracorporeal membrane oxygenation: The role of thrombelastography. Journal of Extra-Corporeal Technology, 27(3), 137-145.

Coagulation monitoring during extracorporeal membrane oxygenation : The role of thrombelastography. / Stammers, A. H.; Willett, Lynne D; Fristoe, L.; Merrill, J.; Stover, T.; Hunt, A.; Morrow, J.; Newberry, J.

In: Journal of Extra-Corporeal Technology, Vol. 27, No. 3, 01.01.1995, p. 137-145.

Research output: Contribution to journalArticle

Stammers, AH, Willett, LD, Fristoe, L, Merrill, J, Stover, T, Hunt, A, Morrow, J & Newberry, J 1995, 'Coagulation monitoring during extracorporeal membrane oxygenation: The role of thrombelastography', Journal of Extra-Corporeal Technology, vol. 27, no. 3, pp. 137-145.
Stammers, A. H. ; Willett, Lynne D ; Fristoe, L. ; Merrill, J. ; Stover, T. ; Hunt, A. ; Morrow, J. ; Newberry, J. / Coagulation monitoring during extracorporeal membrane oxygenation : The role of thrombelastography. In: Journal of Extra-Corporeal Technology. 1995 ; Vol. 27, No. 3. pp. 137-145.
@article{b9428963ac7c4c1e9bb50b59b569c51f,
title = "Coagulation monitoring during extracorporeal membrane oxygenation: The role of thrombelastography",
abstract = "Patients undergoing extracorporeal membrane oxygenation (ECMO) are at an increased risk for developing coagulopathies due to the adverse effects of extracorporeal circulation on the hemostatic mechanism. Methods of determining causative factors of bleeding diathesis are often inconsistent and non-specific. ECMO patients require aggressive transfusion therapy with autogenic blood products to stabilize and maintain hemostasis. The present study evaluated the coagulation status of newborn patients undergoing ECMO therapy, using a viscoelastic monitor (Thrombelastograph -TEG) that measures functional aspects of clot development and stabilization. Seventeen neonatal patients undergoing ECMO for severe respiratory dysfunction were entered into this study. Serial blood samples were obtained and routine coagulation assessment including fibrinogen concentration, platelet count and ionized calcium was performed. In addition, fibrin (ogen) degradation products (FDP), d-Dimers, antithrombin III and plasma free hemoglobin were measured. Transfusion indicators were established and total transfusion requirements recorded. TEG profiles were determined with the use of heparinase, an enzyme that degrades heparin but has little effect on other coagulation factors. The most commonly encountered complication was hemorrhaging which was diagnosed by laboratory and clinical assessment in 11 of 17 patients. Transfusion requirements (measured in ml/kg/ECMO hour) were the following: packed red blood cells -1.34±0.5; platelets -0.71±0.57; fresh frozen plasma - 0.09±0.12; cryoprecipitate 0.05±0.05. Thrombelastograph profiles reflected hemostatic conditions that ranged from severe coagulopathies (DIC) to hypercoagulability. Interpretation of TEG profiles indentified hemostatic abnormalities in 57 of 101 profiles (46.5{\%}), with the most common etiology related to platelet dysfunction. In the non-hemorrhagic group the TEG profiles were normal in 30 of 41 (73.2{\%}) instances, while the hemorrhagic group had 24 of 60 (40{\%}) profiles in the normal range (p<.001). d-Dimers and FDP were elevated in all patients during ECMO despite maintenance of activated clotting times greater than 180 seconds. During ECMO coagulation assessment with the TEG provides useful information for the rapid diagnosis of hemorrhagic conditions, which may help guide transfusion therapy.",
author = "Stammers, {A. H.} and Willett, {Lynne D} and L. Fristoe and J. Merrill and T. Stover and A. Hunt and J. Morrow and J. Newberry",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "27",
pages = "137--145",
journal = "Journal of Extra-Corporeal Technology",
issn = "0022-1058",
publisher = "American Society of Extra-Corporeal Technology",
number = "3",

}

TY - JOUR

T1 - Coagulation monitoring during extracorporeal membrane oxygenation

T2 - The role of thrombelastography

AU - Stammers, A. H.

AU - Willett, Lynne D

AU - Fristoe, L.

AU - Merrill, J.

AU - Stover, T.

AU - Hunt, A.

AU - Morrow, J.

AU - Newberry, J.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Patients undergoing extracorporeal membrane oxygenation (ECMO) are at an increased risk for developing coagulopathies due to the adverse effects of extracorporeal circulation on the hemostatic mechanism. Methods of determining causative factors of bleeding diathesis are often inconsistent and non-specific. ECMO patients require aggressive transfusion therapy with autogenic blood products to stabilize and maintain hemostasis. The present study evaluated the coagulation status of newborn patients undergoing ECMO therapy, using a viscoelastic monitor (Thrombelastograph -TEG) that measures functional aspects of clot development and stabilization. Seventeen neonatal patients undergoing ECMO for severe respiratory dysfunction were entered into this study. Serial blood samples were obtained and routine coagulation assessment including fibrinogen concentration, platelet count and ionized calcium was performed. In addition, fibrin (ogen) degradation products (FDP), d-Dimers, antithrombin III and plasma free hemoglobin were measured. Transfusion indicators were established and total transfusion requirements recorded. TEG profiles were determined with the use of heparinase, an enzyme that degrades heparin but has little effect on other coagulation factors. The most commonly encountered complication was hemorrhaging which was diagnosed by laboratory and clinical assessment in 11 of 17 patients. Transfusion requirements (measured in ml/kg/ECMO hour) were the following: packed red blood cells -1.34±0.5; platelets -0.71±0.57; fresh frozen plasma - 0.09±0.12; cryoprecipitate 0.05±0.05. Thrombelastograph profiles reflected hemostatic conditions that ranged from severe coagulopathies (DIC) to hypercoagulability. Interpretation of TEG profiles indentified hemostatic abnormalities in 57 of 101 profiles (46.5%), with the most common etiology related to platelet dysfunction. In the non-hemorrhagic group the TEG profiles were normal in 30 of 41 (73.2%) instances, while the hemorrhagic group had 24 of 60 (40%) profiles in the normal range (p<.001). d-Dimers and FDP were elevated in all patients during ECMO despite maintenance of activated clotting times greater than 180 seconds. During ECMO coagulation assessment with the TEG provides useful information for the rapid diagnosis of hemorrhagic conditions, which may help guide transfusion therapy.

AB - Patients undergoing extracorporeal membrane oxygenation (ECMO) are at an increased risk for developing coagulopathies due to the adverse effects of extracorporeal circulation on the hemostatic mechanism. Methods of determining causative factors of bleeding diathesis are often inconsistent and non-specific. ECMO patients require aggressive transfusion therapy with autogenic blood products to stabilize and maintain hemostasis. The present study evaluated the coagulation status of newborn patients undergoing ECMO therapy, using a viscoelastic monitor (Thrombelastograph -TEG) that measures functional aspects of clot development and stabilization. Seventeen neonatal patients undergoing ECMO for severe respiratory dysfunction were entered into this study. Serial blood samples were obtained and routine coagulation assessment including fibrinogen concentration, platelet count and ionized calcium was performed. In addition, fibrin (ogen) degradation products (FDP), d-Dimers, antithrombin III and plasma free hemoglobin were measured. Transfusion indicators were established and total transfusion requirements recorded. TEG profiles were determined with the use of heparinase, an enzyme that degrades heparin but has little effect on other coagulation factors. The most commonly encountered complication was hemorrhaging which was diagnosed by laboratory and clinical assessment in 11 of 17 patients. Transfusion requirements (measured in ml/kg/ECMO hour) were the following: packed red blood cells -1.34±0.5; platelets -0.71±0.57; fresh frozen plasma - 0.09±0.12; cryoprecipitate 0.05±0.05. Thrombelastograph profiles reflected hemostatic conditions that ranged from severe coagulopathies (DIC) to hypercoagulability. Interpretation of TEG profiles indentified hemostatic abnormalities in 57 of 101 profiles (46.5%), with the most common etiology related to platelet dysfunction. In the non-hemorrhagic group the TEG profiles were normal in 30 of 41 (73.2%) instances, while the hemorrhagic group had 24 of 60 (40%) profiles in the normal range (p<.001). d-Dimers and FDP were elevated in all patients during ECMO despite maintenance of activated clotting times greater than 180 seconds. During ECMO coagulation assessment with the TEG provides useful information for the rapid diagnosis of hemorrhagic conditions, which may help guide transfusion therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029095497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029095497&partnerID=8YFLogxK

M3 - Article

C2 - 10155358

AN - SCOPUS:0029095497

VL - 27

SP - 137

EP - 145

JO - Journal of Extra-Corporeal Technology

JF - Journal of Extra-Corporeal Technology

SN - 0022-1058

IS - 3

ER -